Scholars@Duke

Association between anti-tuberculosis drug resistance-conferring mutations and treatment outcomes in Myanmar.

Publication ,  Journal Article
Aung, HL; Tun, T; Nyunt, WW; Fong, Y; Crump, JA; Thinn, KK; Aung, ST; Cook, GM
Published in: Infect Dis (Lond)
May 2018
Published version (DOI) Link to item

Duke Scholars

John Andrew Crump
Author John Andrew Crump Medicine, Infectious Diseases

Published In

Infect Dis (Lond)

DOI

10.1080/23744235.2017.1404632

EISSN

2374-4243

Publication Date

May 2018

Volume

50

Issue

5

Start / End Page

388 / 390

Location

England

Related Subject Headings

  • Tuberculosis
  • Treatment Outcome
  • Mycobacterium tuberculosis
  • Myanmar
  • Mutation
  • Humans
  • Antitubercular Agents
  • 4202 Epidemiology
  • 3207 Medical microbiology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Aung, H. L., Tun, T., Nyunt, W. W., Fong, Y., Crump, J. A., Thinn, K. K., … Cook, G. M. (2018). Association between anti-tuberculosis drug resistance-conferring mutations and treatment outcomes in Myanmar. Infect Dis (Lond), 50(5), 388–390. https://doi.org/10.1080/23744235.2017.1404632
Aung, Htin Lin, Thanda Tun, Wint Wint Nyunt, Yang Fong, John A. Crump, Kyi Kyi Thinn, Si Thu Aung, and Gregory M. Cook. “Association between anti-tuberculosis drug resistance-conferring mutations and treatment outcomes in Myanmar.” Infect Dis (Lond) 50, no. 5 (May 2018): 388–90. https://doi.org/10.1080/23744235.2017.1404632.
Aung HL, Tun T, Nyunt WW, Fong Y, Crump JA, Thinn KK, et al. Association between anti-tuberculosis drug resistance-conferring mutations and treatment outcomes in Myanmar. Infect Dis (Lond). 2018 May;50(5):388–90.
Aung, Htin Lin, et al. “Association between anti-tuberculosis drug resistance-conferring mutations and treatment outcomes in Myanmar.” Infect Dis (Lond), vol. 50, no. 5, May 2018, pp. 388–90. Pubmed, doi:10.1080/23744235.2017.1404632.
Aung HL, Tun T, Nyunt WW, Fong Y, Crump JA, Thinn KK, Aung ST, Cook GM. Association between anti-tuberculosis drug resistance-conferring mutations and treatment outcomes in Myanmar. Infect Dis (Lond). 2018 May;50(5):388–390.

Published In

Infect Dis (Lond)

DOI

10.1080/23744235.2017.1404632

EISSN

2374-4243

Publication Date

May 2018

Volume

50

Issue

5

Start / End Page

388 / 390

Location

England

Related Subject Headings

  • Tuberculosis
  • Treatment Outcome
  • Mycobacterium tuberculosis
  • Myanmar
  • Mutation
  • Humans
  • Antitubercular Agents
  • 4202 Epidemiology
  • 3207 Medical microbiology
  • 3202 Clinical sciences